VolitionRX’s (VNRX) Hold Rating Reiterated at D. Boral Capital

D. Boral Capital reaffirmed their hold rating on shares of VolitionRX (NYSEAMERICAN:VNRX) in a report issued on Monday morning, MarketBeat Ratings reports.

Several other brokerages have also recently issued reports on VNRX. HC Wainwright reduced their price objective on VolitionRX from $1.50 to $1.00 and set a “buy” rating on the stock in a research note on Thursday, April 2nd. Citigroup cut VolitionRX to a “hold” rating in a research note on Monday. One equities research analyst has rated the stock with a Strong Buy rating, one has assigned a Buy rating and three have given a Hold rating to the stock. Based on data from MarketBeat.com, the company presently has an average rating of “Moderate Buy” and a consensus price target of $2.33.

VolitionRX Trading Up 0.4%

Shares of NYSEAMERICAN VNRX opened at $0.16 on Monday. The stock has a market cap of $24.99 million, a P/E ratio of -0.72 and a beta of 1.33. VolitionRX has a 12-month low of $0.15 and a 12-month high of $0.94. The business’s fifty day simple moving average is $0.19 and its 200-day simple moving average is $0.29.

VolitionRX’s stock is scheduled to reverse split on Tuesday, April 28th. The 1-20 reverse split was recently announced. The number of shares owned by shareholders will be adjusted after the market closes on Monday, April 27th.

VolitionRX (NYSEAMERICAN:VNRX) last announced its quarterly earnings data on Tuesday, March 31st. The medical research company reported ($0.05) earnings per share (EPS) for the quarter, meeting the consensus estimate of ($0.05). The company had revenue of $0.45 million during the quarter, compared to analyst estimates of $0.71 million. On average, equities analysts forecast that VolitionRX will post -0.11 EPS for the current fiscal year.

Institutional Trading of VolitionRX

Hedge funds and other institutional investors have recently bought and sold shares of the business. Jane Street Group LLC acquired a new stake in VolitionRX in the fourth quarter valued at $28,000. Virtu Financial LLC raised its stake in VolitionRX by 166.6% in the fourth quarter. Virtu Financial LLC now owns 108,581 shares of the medical research company’s stock valued at $28,000 after buying an additional 67,848 shares in the last quarter. Squarepoint Ops LLC acquired a new stake in VolitionRX in the fourth quarter valued at $34,000. Northwestern Mutual Wealth Management Co. acquired a new stake in VolitionRX in the second quarter valued at $52,000. Finally, Citadel Advisors LLC raised its stake in VolitionRX by 70.1% in the third quarter. Citadel Advisors LLC now owns 329,520 shares of the medical research company’s stock valued at $224,000 after buying an additional 135,775 shares in the last quarter. 8.09% of the stock is currently owned by institutional investors and hedge funds.

About VolitionRX

VolitionRX, traded as VNRX on the NYSE American exchange, is a pioneering life sciences company focused on the development and commercialization of minimally invasive diagnostic tests for the early detection of cancer and other diseases. Utilizing proprietary technology to analyze circulating nucleosomes in blood samples, the company’s platform identifies disease-specific epigenetic and biochemical signatures. By offering blood-based screening solutions, VolitionRX aims to deliver alternatives to invasive, costly and time-consuming procedures, potentially improving patient outcomes through earlier diagnosis.

The company’s flagship product suite, branded as Nu.Q, comprises assays designed to detect biomarkers associated with a range of malignancies, including colorectal, lung and pancreatic cancers, as well as other systemic conditions.